We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Medtronic PLC | NYSE:MDT | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.3786 | -0.45% | 83.9214 | 84.71 | 83.77 | 84.58 | 2,078,876 | 16:31:57 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant
Check the appropriate box:
☐ | Preliminary Proxy Statement | |
☐ | CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) | |
☐ | Definitive Proxy Statement | |
☒ | Definitive Additional Materials | |
☐ | Soliciting Material Pursuant to §240.14a-12 |
MEDTRONIC PLC
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒ | No fee required. | |||
☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. | |||
(1) |
Title of each class of securities to which transaction applies:
|
|||
(2) |
Aggregate number of securities to which transaction applies:
|
|||
(3) |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|||
(4) |
Proposed maximum aggregate value of transaction:
|
|||
(5) |
Total fee paid:
|
|||
☐ | Fee paid previously with preliminary materials. | |||
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
(1) |
Amount Previously Paid:
|
|||
(2) |
Form, Schedule or Registration Statement No.:
|
|||
(3) |
Filing Party:
|
|||
(4) |
Date Filed:
|
*** Exercise Your Right to Vote ***
Important Notice Regarding the Availability of Proxy Materials for the
2020 Annual General Meeting to Be Held Virtually on December 11, 2020.
Before You Vote | ||||
How to Access the Proxy Materials
|
How To Vote Please Choose One of the Following Voting Methods
|
|
|
Vote By Internet:
Before The Meeting:
Go to www.proxyvote.com or from a smartphone, scan the QR Barcode above. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.
During The Meeting:
Go to www.virtualshareholdermeeting.com/MDT2020. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.
|
|||
Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.
|
||||
Vote By Phone: To vote by telephone, go to www.proxyvote.com to view the proxy materials and obtain the toll free number to call. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.
|
||||
Voting Items
|
The Board of Directors recommends you vote FOR the following proposals:
|
||||||
|
1. |
To elect, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2021 Annual General Meeting of the Company.
|
||||
Nominees:
|
||||||
1a.
|
Richard H. Anderson | |||||
1b.
|
Craig Arnold | |||||
1c.
|
Scott C. Donnelly | |||||
1d.
|
Andrea J. Goldsmith, Ph.D. | |||||
1e.
|
Randall J. Hogan, III | |||||
1f.
|
Michael O. Leavitt | |||||
1g.
|
James T. Lenehan | |||||
1h.
|
Kevin E. Lofton | |||||
1i.
|
Geoffrey S. Martha | |||||
1j.
|
Elizabeth G. Nabel, M.D. | |||||
1k.
|
Denise M. OLeary | |||||
1l.
|
Kendall J. Powell | |||||
2. |
To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Companys independent auditor for fiscal year 2021 and to authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditors remuneration. |
|||
3. |
To approve, in a non-binding advisory vote, named executive officer compensation (a Say-on-Pay vote). |
|||
4. |
To renew the Boards authority to issue shares. |
|||
5. |
To renew the Boards authority to opt out of pre-emption rights. |
|||
6. |
Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. |
|||
7. |
Transacting any other business that may properly come before the meeting. |
1 Year Medtronic Chart |
1 Month Medtronic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions